GlassScriptPhysician profile
Manisha S Thakur
NPI 1639152275
$12,724.59
in general payments reported to CMS, 2019-2025
55 companies · $1,663 in 2025
The $1,663 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,545 · 2020: $1,587 · 2021: $2,049 · 2022: $1,757 · 2023: $2,147 · 2024: $1,975 · 2025: $1,663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,785.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,532.52 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $1,414.98 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $734.94 | 2019-2025 | |
| Amgen INC. | $722.48 | 2019-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $592.08 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $521.40 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $486.42 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $444.07 | 2019-2025 | Airsupra, Farxiga, Wainua |
| Novartis Pharmaceuticals Corporation | $407.49 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $375.30 | 2021-2025 | Rexulti |
| Lilly USA, LLC | $374.56 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Allergan, INC. | $285.33 | 2019-2020 | |
| Astellas Pharma US INC | $260.82 | 2019-2024 | Veozah |
| Merck Sharp & Dohme LLC | $250.70 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $239.55 | 2023-2025 | Caplyta |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manisha Thakur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.